Janice Dara, MD
Family Practice · Alexandria, LANPI 1952757304
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Lilly USA, LLC at 27.4% of the total. Reporting peaked in 2019 at $410 and has fallen 66.1% since, to $139 in 2025. Among family practice clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$213
- AbbVie$140
- Novo Nordisk$130
- GSK$121
- Takeda Pharmaceuticals U.S.A., Inc.$46
- Pfizer$45
- plus $84 from 6 others
What the payments were for
- Food & beverage$778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $213 |
| AbbVie | 2 | $140 |
| Novo Nordisk | 5 | $130 |
| GSK | 8 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Pfizer | 3 | $45 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$778 in reported general payments places this provider in the 95th percentile of 69 family practice providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 221 | $262,712 |
| JardianceEmpagliflozin | 238 | $209,737 |
| OzempicSemaglutide | 147 | $176,403 |
| TrulicityDulaglutide | 120 | $146,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 127 | $90,671 |
| EliquisApixaban | 107 | $89,978 |
| RybelsusSemaglutide | 66 | $87,488 |
| FarxigaDapagliflozin Propanediol | 96 | $86,417 |
| Dupixent PenDupilumab | 21 | $75,556 |
| LinzessLinaclotide | 87 | $71,632 |
| XareltoRivaroxaban | 45 | $40,687 |
| EntrestoSacubitril/Valsartan | 52 | $40,417 |
| JanuviaSitagliptin Phosphate | 36 | $36,562 |
| RexultiBrexpiprazole | 14 | $36,289 |
| MyrbetriqMirabegron | 37 | $29,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $213 | $409,222341 claims |
| Novo NordiskOzempic, Rybelsus | $130 | $263,890213 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $12 | $215,655250 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $121 | $110,495164 claims |
| PfizerEliquis, Nurtec Odt | $45 | $105,803120 claims |
| AbbVieLinzess, Vraylar, Synthroid | $140 | $104,735155 claims |
| AstraZenecaFarxiga, Symbicort | $16 | $90,437114 claims |
| MerckJanuvia, Belsomra | $11 | $42,82750 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $29,84037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 family practice providers in Louisiana.
Other family practice in Alexandria
- John BrianAlexandria$0
- Jade ParkAlexandria$0
- Russel SmithAlexandria$0
- Cindy DollarMonroe$30
- James ThomasShreveport$22
- Ebony JuakaliSlidell$0
- Asha Robinson-ParksJefferson$0
- Marne' DevillierSulphur$0
- Michelle FishNew Orleans$0
- Michael ChanlerMinden$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.